Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa
- 31 March 2008
- Vol. 26 (22) , 2788-2795
- https://doi.org/10.1016/j.vaccine.2008.02.071
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Clinical experience with plasmid DNA- and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell inductionJournal of General Virology, 2007
- HIV Type 1 Subtypes among STI Patients in Nairobi: A Genotypic Study Based on PartialpolGene SequencingAIDS Research and Human Retroviruses, 2006
- Induction of Multifunctional Human Immunodeficiency Virus Type 1 (HIV-1)-Specific T Cells Capable of Proliferation in Healthy Subjects by Using a Prime-Boost Regimen of DNA- and Modified Vaccinia Virus Ankara-Vectored Vaccines Expressing HIV-1 Gag Coupled to CD8+T-Cell EpitopesJournal of Virology, 2006
- Expansion and Diversification of Virus-Specific T Cells following Immunization of Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Individuals with a Recombinant Modified Vaccinia Virus Ankara/HIV-1 Gag VaccineJournal of Virology, 2006
- Biodistribution of DNA Plasmid Vaccines against HIV-1, Ebola, Severe Acute Respiratory Syndrome, or West Nile Virus Is Similar, without Integration, despite Differing Plasmid Backbones or Gene InsertsToxicological Sciences, 2006
- Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteersVaccine, 2006
- Electroporation for targeted gene transferExpert Opinion on Drug Delivery, 2005
- Epidermal delivery of protein and DNA vaccinesExpert Opinion on Drug Delivery, 2005
- Enhancement of human immunodeficiency virus type 1‐DNA vaccine potency through incorporation of T‐helper 1 molecular adjuvantsImmunological Reviews, 2004
- A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humansJournal of General Virology, 2004